← The MonexusScience
A gut-first drug rewrites the early thinking on fatty liver disease
A DT-109 candidate that repairs gut tissue reversed severe fatty liver disease in animal studies, reframing a condition long treated as a lifestyle problem.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- https://en.wikipedia.org/wiki/Metabolic_dysfunction%E2%80%93associated_steatotic_liver_disease
- https://en.wikipedia.org/wiki/Obeticholic_acid
- https://en.wikipedia.org/wiki/Semaglutide
- https://en.wikipedia.org/wiki/Metabolic_dysfunction%E2%80%93associated_steatohepatitis
Source record supplied with this article
© 2026 Monexus Media · AI-native reporting from public-source material